SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

Supriya Lifescience

BSE: 543434 29 Jun 2025
Healthcare
₹ 673
Supriya Lifescience Limited specializes in Pharmaceuticals within the Healthcare sector.

Supriya Lifescience - Share Price & Details

Market Cap
₹5,544
High /Low
842.0 / 368.0
Stock P/E
29.5
Book Value
₹124.0
Dividend Yield
0.12
ROCE
27.4
ROE
₹20.7
Face Value
2.0
PEG Ratio
1.42
EVEBITDA
₹20.2
Debt
5.38
CMP / FCF
-224.0
Debt to equity
₹0.01
NP Ann
188
High price all time
842.0
Piotroski score
₹7.0
Graham Number
255.0
No. Eq. Shares
8.05
Net CF
₹4.20
Net profit
188
Price to book value
5.56
Interest Coverage
₹148.0
Low price all time
170.0
Industry PE
32.7
Reserves
₹981
Free Cash Flow
₹2.30

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
LOOKS HEALTH SERVICES LIMITEDNANANANA5.11256.0
Triochem Products Ltd.,NANANANA0
Supriya Lifescience LimitedNANANANA5,54429.5
SUN PHARMA ADVANCED RESEARCH C271.9-597.7271.9-1.845384
Thyrocare Technologies Limited1784.1219.51738.74.07528258.2

Peer Comparison Chart


About Supriya Lifescience

Supriya Lifescience Limited, with Security Code 543434, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

Saloni and Shivani Wagh of Supriya Lifescience Featured in 2025 Candere Hurun India Women Leaders List Amid Record Revenue Year

(12 Jun 2025)
Saloni Wagh and Shivani Wagh of Supriya Lifescience have been named in the 2025 Candere Hurun India Women Leaders List,...
Read more →

Dr. Saloni Wagh, Shivani Wagh Of Supriya Lifescience In 2025 Candere Hurun India Women Leaders List

(07 Jun 2025)
The list, a collaboration between Candere and Hurun India, celebrates 95 of the country's most exceptional women leaders who are redefining...
Read more →

Supriya Lifescience Delivers Record-Breaking FY25 with 22% Revenue Growth

(29 May 2025)
Mumbai : The unaudited financial statements for the quarter and full year ended March 31, 2025, have been released by Supriya Lifescience...
Read more →

Pharma stock jumps 8% after company forecasts 20% revenue growth

(29 May 2025)
A leading pharmaceutical company witnessed an 8 percent surge in its stock price after unveiling ambitious plans to achieve 20 percent...
Read more →

Supriya Lifescience Delivers Record FY25 Performance with 22 Percent Revenue Growth and 38 Percent Surge in Q4 PAT

(28 May 2025)
Expansion in global markets, backward integration, and therapeutic focus drive earnings momentum across quarters Supriya Lifescience Ltd.,...
Read more →

Supriya Lifescience guides for over 20% revenue growth, expects robust margins ahead

(28 May 2025)
Backward integration, regulated market expansion, and new contracts to drive growth, says MD Saloni Wagh.
Read more →